Ernexa Therapeutics completes manufacturing milestones for ERNA-101

Ernexa Therapeutics (NASDAQ: ERNA) completed process development activities for its ERNA-101 cell therapy and transitioned into Good Manufacturing Practice manufacturing in preparation for clinical development. The company announced these milestones as it prepares for an Investigational New Drug submission planned for the third quarter of 2026.

The Cambridge, Massachusetts-based biotechnology company said technology transfer activities for ERNA-101 are underway, supporting the planned IND submission timeline. ERNA-101 is designed to activate and regulate immune system responses to recognize and attack cancer cells.

"Completing process development and advancing into GMP manufacturing are critical steps toward IND clearance and the launch of our first-in-human clinical study for ERNA-101," said Sanjeev Luther, chief executive officer of Ernexa Therapeutics.

Ernexa develops cell therapies for advanced cancer and autoimmune diseases using engineered induced pluripotent stem cells transformed into induced mesenchymal stem cells. The company's technology provides allogeneic synthetic cells as an off-the-shelf treatment solution without requiring patient-specific cell harvesting.

The company's initial focus centers on developing ERNA-101 for ovarian cancer treatment. Ernexa also develops ERNA-201, a cell therapy product designed to target inflammation and treat autoimmune disease.

The completion of these manufacturing milestones positions Ernexa for its transition to a clinical-stage biotechnology company following the anticipated IND submission and clearance for first-in-human studies.

You May Also Be Interested In

• System1 launches Dogpile Fetch, a search API for AI agents
• Greenland Mines adopts one-year stockholder rights plan
• Onfolio ends helium deal, refocuses on online business acquisitions